Zydus Cadila gets USFDA nod for anti-hypertensive tablets
New Delhi, Apr 25: Drug firm Cadila Healthcare today said Zydus Cadila has received approval from the US health regulator to market its anti-hypertensive olmesartan medoxomil tablets in the American market.
The company has received "final approval from the United States Food and Drug Administration (USFDA) to market olmesartan medoxomil tablets in the strengths of 5 mg, 20 mg and 40 mg", Cadila Healthcare said in a filing to BSE.
The drug is an anti-hypertensive and will be produced at the group's formulations manufacturing facility in Ahmedabad, it added.
As per IMS MAT February 2017, the estimated sales for olmesartan is USD 982 million, Cadila Healthcare said.
The group currently has over 110 approvals and has so far filed 300 abbreviated new drug applications (ANDA)s, it added.
Shares of Cadila Healthcare were today trading at Rs 456.60 per scrip in the afternoon trade on BSE, up 1.20 per cent from its previous close.
The company has received "final approval from the United States Food and Drug Administration (USFDA) to market olmesartan medoxomil tablets in the strengths of 5 mg, 20 mg and 40 mg", Cadila Healthcare said in a filing to BSE.
The drug is an anti-hypertensive and will be produced at the group's formulations manufacturing facility in Ahmedabad, it added.
As per IMS MAT February 2017, the estimated sales for olmesartan is USD 982 million, Cadila Healthcare said.
The group currently has over 110 approvals and has so far filed 300 abbreviated new drug applications (ANDA)s, it added.
Shares of Cadila Healthcare were today trading at Rs 456.60 per scrip in the afternoon trade on BSE, up 1.20 per cent from its previous close.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd